Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Aurora Spine slightly increases revenue and improves gross margin in Q1 2026

Aurora Spine reported Q1 2026 revenue of $4.44 million (+0.4% year‑on‑year) with a significantly improved gross profit margin of 62.6% (up 460 basis points). Net loss narrowed 42% to $203,000, and EBITDAC was positive at $107,000. The stock fell 2.04% to $0.245 after the results. The company plans to expand its sales team by 50% and expects growth from the launch of SiLO-X in the second half of the year. » More on de.investing.com
Aurora Spine reports record revenue of $5.02 million in Q4 2025

Aurora Spine posted record revenue of $5.02 million in Q4 2025, up 14% sequentially and 6.8% year-over-year. Gross profit margin improved to 62.4% and net loss narrowed to $41,000 from $653,000 in the year-ago quarter. ZIP and SiLO contributed 60% of revenue; EBITDAC rose to $301,000. For 2026, management expects growth from DEXA technology, notably the DEXA-L implant, and plans to expand the sales team by 50%. » More on de.investing.com
Aurora Spine reports Q3 2025 revenue decline despite product launches

Aurora Spine recorded a 7.1% revenue decline in the third quarter of 2025 to USD 4.43 million, with a net loss of USD 842,000 and cash on hand of just under USD 700,000. Gross margin improved slightly to 60.9% and operating expenses fell to USD 2.81 million. The company launched the facet pain implant Hydra ARO and the anterior lumbar fusion system DEXA L, is targeting monthly revenue above USD 1.4 million, and plans to expand the DEXA L kits in 2026. The stock fell 6.67% after the results were released. » More on de.investing.com
Aurora Spine Corporation reports 10.2% revenue growth for Q2 2025 and remains unprofitable

Aurora Spine Corporation increased revenue in the second quarter of 2025 by 10.2% to $4.5 million, with an improved gross margin of 62.2%, but still posted a net loss of $199,000. The company is introducing new products such as Hydra Arrow and DEXA L, plans to expand its sales team, and expects further growth in H2 2025 driven by rising demand for minimally invasive spinal procedures. Management expressed optimism for the second half of the year but flagged risks from competition and macroeconomic uncertainty. » More on de.investing.com

Financials

In the last quarter, AURORA SPINE CORP. had revenue of €3.12m and net profit of -€712.85k

(EUR)	June 2026	YoY
Revenue	3.12m	18.13%
Gross profit	410.48k	82.72%
Net profit	-712.85k	322.73%
EBITDA	-460.61k	541.45%

Fundamentals

Metric	Value
Market capitalization	€4.43m
Number of shares	78.09m
52-week high/low	€0.21 - €0.0567
Dividends	No
Beta	-0.56
P/E ratio	-4.32
PEG ratio	0.04
P/B ratio	1.84
P/S ratio	0.30

Company profile

Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.